{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035917","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.411836+00:00","generated_at":"2026-05-25T01:42:39.502828+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026","bullets":["Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.","Cash, equivalents and marketable securities $133.6M at Dec 31, 2024; runway into Q2 2026.","PRT3789 showed 5 confirmed partial responses in NSCLC, gastric, esophageal cancer; safety acceptable.","PRT7732 oral SMARCA2 degrader Phase 1 enrollment ongoing; interim data expected H2 2025.","Bryant Lim named permanent CFO; company to seek partner for PRT2527 CDK9 program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035917","json":"https://secwatch.observer/filing/0000950170-25-035917.json","markdown":"https://secwatch.observer/filing/0000950170-25-035917.md","text":"https://secwatch.observer/filing/0000950170-25-035917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/0000950170-25-035917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/prld-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:42:39.502828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}